Loading data for BOLD — first visit, this takes a few seconds.
Boundless Bio, Inc. (BOLD)
NasdaqGS: BOLD
· 即時價格 · USD
2.87
-0.02 (-0.69%)
收盤價： Sep 04, 2026, 8:00 PM
2.87
+0.00%
盤後: 4:10 PM
股價、關鍵數字和最新消息，都在這一頁。
Boundless Bio, Inc.（BOLD）股價、分析與資料
無可用資料
| 買價 | 2.05 |
| 市值 | 65.3M |
| 營收 (ttm) | n/a |
| 淨利（ttm） | -64M |
| 0.44 | |
| -2.85 | |
| n/a | |
| -2.93 | |
| P/B (ttm) | 0.98 |
| P/S (ttm) | 0.00 |
| 財報日期 | n/a |
| 賣價 | 3.66 |
| 成交量 | 20,000 |
| 20 日平均成交量 | 1,276,977 |
| 開盤價 | 2.86 |
| 前收盤價 | 2.89 |
| 當日區間 | 2.86 - 2.89 |
| 52 週範圍 | 0.96 - 3.16 |
| 分析師 | n/a |
| 目標價 | n/a |
| 股利 | n/a |
| 除息日 | n/a |
關於 BOLD
Boundless Bio, Inc., a clinical-stage oncology company, develops interrogating extrachromosomal DNA (ecDNA) directed therapies for treating patients with oncogene amplified cancers. Its lead product candidate is BBI-940, an ecDNA-directed therapeutic candidate (ecDTx) that is in Phase 1/2 clinical trial in patients with estrogen receptor positive and human epidermal growth factor receptor 2 negative breast cancer, as well as patients with triple-...
完整的公司簡介財報驚奇
Boundless Bio 已於 Aug 7, 2026 公布季度財報：
- 營收為 $0 低於預期 $0, 年增 NaN% 成長.
- 每股盈餘為 -1.06 低於預期 -0.48, 年增 -51.43% 下滑.
第 1 頁，共 2 頁